90071-62-8 Usage
Description
H-D-PRO-OTBU, also known as D-Proline tert-Butyl Ester, is a chemical compound derived from D-proline. It is an oil with a tert-butyl ester group attached to it, which makes it a versatile building block in organic synthesis.
Uses
Used in Pharmaceutical Industry:
H-D-PRO-OTBU is used as a key intermediate in the synthesis of various pharmaceutical compounds for their therapeutic applications. It plays a crucial role in the production of (R)-(+)-N-Boc-Pipecolic Acid, (S)-(-)-Coniine, (S)-(+)-Pelletierine, (+)-.beta.-Conhydrine, and (S)-(-)-Ropivacaine. These compounds have diverse applications in medicine, such as pain management, muscle relaxation, and treatment of neurological disorders.
Additionally, H-D-PRO-OTBU is used in the formal synthesis of (-)-Lasubine II and (+)-Cermizine C, which are complex organic molecules with potential pharmaceutical applications. The tert-butyl ester group in H-D-PRO-OTBU allows for selective protection and deprotection during the synthesis process, making it an essential component in the development of these complex molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 90071-62-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,0,0,7 and 1 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 90071-62:
(7*9)+(6*0)+(5*0)+(4*7)+(3*1)+(2*6)+(1*2)=108
108 % 10 = 8
So 90071-62-8 is a valid CAS Registry Number.
InChI:InChI=1/C9H17NO2/c1-9(2,3)12-8(11)7-5-4-6-10-7/h7,10H,4-6H2,1-3H3/t7-/m1/s1
90071-62-8Relevant articles and documents
Stereoselective synthesis of cyclic amino acids via asymmetric phase-transfer catalytic alkylation
Kano, Taichi,Kumano, Takeshi,Sakamoto, Ryu,Maruoka, Keiji
supporting information, p. 271 - 278 (2013/02/25)
An asymmetric synthesis of cyclic amino acids having piperidine and azepane core structures was realized starting from readily available glycine and alanine esters by combination of phase-transfer catalyzed asymmetric alkylation and subsequent reductive a
D-proline derivatives
-
, (2008/06/13)
New compounds have the formula: wherein R, R1, X and Y have the meanings described herein. Methods are set forth for synthesizing these compounds and using these compounds to treat diseases associated with amyloidosis, such as Alzheimer's disease, maturity onset diabetes mellitus, familial amyloid polyneuropathy, scrapie, and Kreuzfeld-Jacob disease.